|
Midtown Urology Division of Medical Research
- A phase III, randomized, double-blind, placebo-controlled, safety and efficacy trial of flibanserin in premenopausal women with hypoactive sexual desire disorder in North America
Ongoing since July 2006
Sponsors: Boehringer Ingelheim Pharmaceuticals, Inc.
Website: www.decreasedsexualdesire.com
- A phase III, randomized, double-blind, placebo controlled, multi-center efficacy and safety study of toremifene citrate for prevention of prostate cancer in men with High Grade PIN (prostatic intraepithelial neoplasia)
Ongoing since January 2005
Sponsors: GTx The Men’s Biotech Company
- A phase III, prospective, open label study to evaluate the ability of MUSE (intraurethral alprostadil) to decrease erectile function recovery time after bilateral nerve- sparing radical prostatectomy
Ongoing since September 2005
Sponsors: Vivus, Inc.
- A phase III, double-blind, placebo-controlled study evaluating the effect of selenium and vitamin E alone and in combination on clinical evidence of prostate cancer
Ongoing since October 2002
Sponsors: National Cancer Institute and the Southwest Oncology Group
- A multicenter, prospective, randomized, masked, two-armed study to evaluate the safety and effectiveness of the AttenueX Intravesical System in the management of females with stress urinary incontinence
Ongoing since May 2006
Sponsors: Solace Therapeutics, Inc.
Website: www.bladdercomfort.com
- A multicenter, phase II, open- labeled study to assess the effects, safety, and quality of life associated with VTP (vascular, targeted photodynamic) therapy in low- risk, localized prostate cancer patients
Anticipated start date: September 2007
Sponsors: Steba Biotech
Past Research Studies
- A Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy
Ongoing since June 2005
Sponsors: GTx The Men's Biotech Company
-
A Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Bone Fractures in Men with High Grade Prostatic Intraepithelial Neoplasia
Ongoing since February 2005
Sponsors: GTx The Men's Biotech Company
- A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women with Female Sexual Arousal Disorder (FSAD)
Ongoing since February 2005
Sponsors: Vivus, Inc.
- Attitudes of African Americans Toward Genetic Testing for Prostate Cancer Risk
Ongoing since August 2003
Sponsors: National Institutes of Health (NIH) and National Institute of General Medical Sciences (NIGMS)
- Female Sexual Disorder (FSD) Study
Ongoing since January 2003
Sponsor: Independent Study
- A Double-Blind, Placebo-Controlled Study of the Effect of Zoledronic Acid on Bone Mineral Density in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Ongoing since May 2003
Sponsors: Novartis Pharmaceutical Corp. and The University of Chicago
- Attitudes of African Americans Toward Genetic Testing for Prostate Cancer Risk
Ongoing since August 2003
Sponsors: National Institutes of Health (NIH) and National Institute of General Medical Sciences (NIGMS)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Ongoing since August 2003
Sponsors: GlaxoSmithKline
- The Role of Alpha-Blockade in the management of LUTS in Women
Length of study: 11/03-4/04
Sponsor: Boehringer-Ingelheim
- High Grade Prostate Intraepithelial Neoplasia (PIN) Study
Length of study: 5/02-4/04
Sponsor: GTx, Inc.
- The African American Hereditary Prostate Cancer Study
Length of study: 3/98-3/04
Sponsors: National Institutes of Health and Howard University
- Validation Study of the Abbott Urinary Symptom Questionnaire (AUSQ) for Urinary Incontinence and the Overactive Bladder
Length of study: 05/01-07/01
Sponsor: Abbott Laboratories
- An Open-label Comparison of Neoadjuvant Hormonal Therapy (NHT) With Abarelix Depot 100 mg IM or Lupron Depot®® 7.5 mg IM in Patients With Prostate Cancer Planned to Undergo Brachytherapy or External-beam Radiation Therapy
Length of study: 06/01-10/01
Sponsor: Amgen
- A Patient Acceptability Study of a Once-Daily Formulation of Tolterodine. A Phase IIIB, Open-Label, Single-Arm Trial in Adult Patients with Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence
Length of study: 11/00-06/01
Sponsor: Pharmacia & Upjohn
- Detrol in the Community (DECO) Study
Length of study: 08/00-03/01
Sponsor: Innovative Health Solutions
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed-Dose, Parallel Group, 6-Month Comparison Study To Investigate The Efficacy And Safety Of The Phosphodiesterase Type V Inhibitor BAY 38-9456 In Males With Erectile Dysfunction
Length of study: 6/00-4/01
Sponsor: Bayer Corporation
- The Effect of Neoadjuvant Hormonal Therapy Prior to Brachytherapy in the Treatment of Localized Prostate Cancer in African American Men
Length of study: 7/00-2/01
Sponsor: Integrated Therapeutics Group, Inc., a subsidiary of Schering-Plough
- An Open Label Study to Evaluate Patient Acceptance and Safety of OROS Oxybutynin Chloride in Urge Urinary Incontinence
Sponsor: ALZA
- A Multicenter Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effect of 100mg ZD6169 Once Daily in Subjects with Idiopathic Detrusor Instability
Sponsor: Zeneca Pharmaceuticals
- An Open-label, Multi-center, Single-arm Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in African American, Hispanic and Caucasian Males with Erectile Dysfunction
Sponsor: Bayer Corporation
- Efficacy of Tolterodine ER vs. Placebo for the Symptom of Urgency and the Improvement in Bladder Condition
Length of study: 10/02-2/03
Sponsor: Pharmacia, Inc.
|
Ongoing Research Studies: